ESOC 2025 | The need for more precise biomarkers to guide secondary stroke prevention
Steffen Tiedt, MD, PhD, Ludwig-Maximilians-University, Munich, Germany, emphasizes the need for more precise biomarkers to guide secondary preventive treatment decisions in stroke patients. Dr Tiedt highlights the potential of novel biomarkers, including blood-based and imaging-based approaches, to elucidate the etiology of stroke and inform targeted interventions. This interview took place at the 11th European Stroke Organisation Conference (ESOC) in Helsinki, Finland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
In fact, I think we already do use biomarkers to lead secondary preventive treatment decisions. In a way that for example atrial fibrillation is in some ways defined by an EKG biomarker. But the field is aiming towards using more fine-tuned, more granular, more precise biomarkers, both blood-based and also imaging or from other modalities such as from an EKG. Because in fact secondary prevention relies on defining the etiology of the patient, the cause that led initially to the stroke of an individual patient and we are not good at doing this clinically...
In fact, I think we already do use biomarkers to lead secondary preventive treatment decisions. In a way that for example atrial fibrillation is in some ways defined by an EKG biomarker. But the field is aiming towards using more fine-tuned, more granular, more precise biomarkers, both blood-based and also imaging or from other modalities such as from an EKG. Because in fact secondary prevention relies on defining the etiology of the patient, the cause that led initially to the stroke of an individual patient and we are not good at doing this clinically. Up to 40% or 50% of patients we do not know the etiology so we need novel tools, novel biomarkers to define this, to understand the underlying mechanisms, and then to guide secondary prevention. And this will all be elaborated on tomorrow in this teaching course.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Consulting fees: Quanterix.
